PROKIDNEY CORP.
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
PROK | NDAQ
Overview
Corporate Details
- ISIN(s):
- KYG8253W1096 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2000 FRONTIS PLAZA BLVD., 27103 WINSTON-SALEM
- Website:
- https://prokidney.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ProKidney Corp. is a late clinical-stage biotechnology company pioneering the development of cellular therapies for Chronic Kidney Disease (CKD). The company's lead product candidate, rilparencel (formerly REACT®), is a first-in-class, renal autologous cell therapy designed to preserve kidney function. It targets patients with advanced CKD (Stage 3b/4), particularly those with diabetes, a population with high unmet medical needs and limited treatment options. ProKidney's mission is to develop a therapy that has the potential to delay or eliminate the need for dialysis, aiming to transform the therapeutic landscape for CKD.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all PROKIDNEY CORP. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for PROKIDNEY CORP.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for PROKIDNEY CORP. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
